CATALYST HEALTH VENTURES - Key Persons

Dr. Kaplan is an active medical device entrepreneur who has been on the founding teams of several venture-backed medical device companies including Conformal Medical, Tryton Medical, LocalMed and Perclose (acquired by Abbott). He has consulted to many medical device companies and was an Entrepreneur-In-Residence at Three Arch Partners. Aaron is a practicing interventional cardiologist at Dartmouth-Hitchcock Medical Center and a Professor of Medicine at the Geisel School of Medicine at Dartmouth. In addition, he directs the Synergy Clinician-Entrepreneur Fellowship and chairs the Dartmouth Device Development Symposium. Prior to joining the Dartmouth faculty, Dr. Kaplan was Director of Interventional Cardiology at the Palo Alto VA and served on the faculty at Stanford University. Aaron has more than 65 peer-reviewed papers, 45 U.S. Patents, and was inducted into the National Academy of Inventors (Class of 2015). He received a B.S. in Engineering Sciences (Cum Laude) from Tufts University, an M.D. from Wake Forest University, medical training at Northwestern University and cardiology training at Stanford University.

Mr. Levine is an entrepreneur with over 35 years of engineering, marketing and general business experience developing medical devices and starting companies. He is a co-founder of Conformal Medical. He previously held a position in business development for medical devices at Harvard University's Wyss Institute for Biologically Inspired Engineering. In 2003, Andy founded GI Dynamics, which developed an endoscopic device for the treatment of diabetes. In 2000 he was a co-founder of Seedling Enterprises, a medical device incubator that started GI Dynamics, Lumerx and Angstrom Medical and licensed out two technologies: IsoCool (J&J) and a Multipurpose Laparoscopic Instrument (Aesculap). Additional start-ups include EnteraStim (GI motility), EndoCellutions (regenerative medicine devices), Microsurge (laparoscopic instruments) and Bard's Reproductive Systems (fertility devices). Andy's diverse experience includes work to conceptualize, design, develop and commercialize products with applications in cardiovascular medicine, gastroenterology, gynecology, general surgery, thoracic surgery, and urology. He possesses technical expertise in biomaterials, mechanism design, fluid mechanics and heat transfer, holds over 70 patents and has authored over 20 technical publications. He holds a M.S. in Mechanical Engineering from the University of Wisconsin-Madison and a B.S. in Mechanical Engineering from Tufts University.

Job Titles:

• Founder
• Managing Partner
• Founder & Managing Partner View Bio

Darshana is a Founder and Managing Partner of Catalyst Health Ventures (CHV). She is actively involved in all aspects of fund management including investments and capital raising and has led several investments in the medical device, women's health and diagnostics markets. She led CHV's investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive and Rejoni. She currently (or previously) represents CHV on the Boards of all companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.

Job Titles:

• CFO
• CFO View Bio
• Chief Financial Officer of CHV

Dave is the Chief Financial Officer of CHV. He is responsible for the financial management, reporting, audit, tax, and administrative functions of CHV and brings 20 years of finance, legal and operational experience to the firm. Prior to joining CHV, Dave held senior roles at two of Catalyst's portfolio companies, serving most recently as Chief Operating Officer at PanTher Therapeutics after previously serving as Chief Financial Officer at Lantos Technologies. Prior to that, he was the Chief Financial Officer at AgNovos Healthcare, where he led financial and administrative operations. Before working in industry, Dave was an investment banker at J.P. Morgan in New York, where he advised companies and investment firms on mergers, acquisitions, divestitures, IPOs, follow-on offerings, and debt financings. He began his career as a corporate attorney at Gibson, Dunn & Crutcher, where he focused his practice on M&A and securities offerings. Dave received a J.D. from the University of Pennsylvania School of Law and a B.A. from Colorado State University.

Job Titles:

• Venture Fellow

Job Titles:

• Founder
• Managing Partner
• Founder & Managing Partner View Bio

Josh is a Founder and Managing Partner of CHV and has been a member of the Investment Committees of the general partners of CHV I and CHV II since 2008. He is actively involved in all aspects of fund management including investments and capital raising and has led CHV I and CHV II investments in the medical device, women's health and molecular diagnostics markets. He led CHV's investments in Allegro Diagnostics (acquired by Veracyte), Vortex Medical (acquired by AngioDynamics), SevenOaks Biosystems (acquired by Medline), Sera Prognostics (NASD: SERA), Pavilion Medical, Saphena Medical, Cruzar Medsystems, Conformal Medical, Brixton Biosciences, EyeCool Therapeutics, and Epitel. He is a Director of Sera Prognostics, Pavilion Medical, Saphena Medical, and Cruzar Medsystems, and a past Director of Allegro Diagnostics, Vortex Medical, and SevenOaks Biosciences. From 2000 to 2007, Josh was the Managing Partner of Catalyst Health and Technology Partners, LLC., an organization that made early-stage investments in healthcare and technology focused companies. Relevant investments he led include Novazyme Pharmaceuticals (acquired by Genzyme), BioTrove (acquired by Life Technologies), and Biocius Life Sciences (acquired by Agilent Technologies). He was previously the Chairman of, a Director of Biocius Life Sciences, and a Board Observer to Novazyme Pharmaceuticals. From 1997 to 2000, he was a Manager at the Lucas Group, a boutique strategy-consulting firm, where he led engagements advising healthcare, life science, and technology-based companies. In 1990, Josh co-founded, managed, and built a new business unit at Russelectric, a privately held engineering technology firm that is now part of Siemens. In five years, the business achieved annual sales in excess of $5 million and employed 15 engineers and technicians. Josh previously held project and engineering management positions at Pratt & Whitney Aircraft, focused on the integration of hardware and software for the control system of the USAF F-22 fighter engine.

Job Titles:

• Marketing & Administrative Associate
• Marketing & Administrative Associate View Bio

Julie supports the CHV team with a variety of tasks including scheduling, database management, accounts payable, investor reporting, and general office administration. Previously, she was working in sales at a senior living community navigating the challenges of guiding seniors and their families through a difficult life transition. Julie received a B.S. from Endicott College.

Mr. McCafferty has over 40 years of experience in venture capital and private equity and was a founder of CHV's predecessor firm, Catalyst Health and Technology Partners, LLC. Kevin began his career at First Chicago Ventures and later joined Madison Dearborn Partners, starting their Boston office. He then founded New England Capital Management and then New England Capital Partners, both focused on acquiring small to medium sized operating companies. Kevin's investment experience has spanned a broad spectrum of corporate maturity and risk/reward profiles, ranging from seed-stage to leveraged buyouts. Kevin holds a B.A. from Harvard College and an M.B.A. from The University of Chicago.

Job Titles:

• CEO of Kojin Therapeutics

Ms. Greenwood is the CEO of Kojin Therapeutics and a leading figure in the biotech and digital health world. She has vast experience as an executive, investor, and company builder in the biotech, life sciences, diagnostics, and tech sectors. Most recently, she has served as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital, which she has built and launched. Previously, Ms. Greenwood served in leadership roles at Google Life Sciences, Verily, and was a VP of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub. Ms. Greenwood has led $5B+ in deals and investments across multiple therapeutic areas and life sciences globally. Additionally, she has co-founded companies in the oncology, AI/ML, women's health and microbiome spaces. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.

Job Titles:

• Medical Oncologist

Dr. Bhandari is a Medical Oncologist at The Christ Hospital in Cincinnati with special interests in lung, breast and head and neck cancers and has peer-reviewed publications in cancer research published in several international journals. In addition to his clinical practice, Manish is an active angel investor and is the Managing Partner of the Angel Physicians Fund. Prior to entering clinical practice, he was in the strategy practice of McKinsey & Company and held a leadership role at CVS. He holds an A.B. in Molecular Biology and Human Genetics from The University of California, Berkeley, and an M.D. from Harvard Medical School.

Job Titles:

• Investment Analyst
• Investment Analyst at CHV
• Investment Analyst View Bio

Mimi is an Investment Analyst at CHV. She is actively involved in managing the deal pipeline, assessing new opportunities, and performing company diligence for our investments. Prior to working at CHV, Mimi was an Innovation and Operations Analyst at Brigham and Women's Hospital in their Digital Innovation Hub, providing product management and project management for innovative pilots along with evaluating new digital health opportunities for the Mass General Brigham Health system. She received her B.A in Economics from The University of Notre Dame.

Job Titles:

• Member of the Executive Committee
• Partner

Mr. Vigoda is a Partner and Member of the Executive Committee at Rubin and Rudman in Boston and was a founder of CHV's predecessor firm, Catalyst Health and Technology Partners, LLC. Rob has practiced estate planning, estate administration and business succession law for over 35 years and is a member of the Massachusetts and Florida bars. Rob has repeatedly been recognized among the top attorneys in Boston, New England and nationally by Boston Magazine, Super Lawyers, and Worth magazine. He holds a B.A. from the University of Rochester and a J.D. from The University of Miami School of Law.

Job Titles:

• Founder and Former CEO of NVision Medical

Ms. Sarna is the founder and former CEO of nVision Medical, acquired by Boston Scientific (NYSE: BSX), a CHV I portfolio company. Darshana has known Surbhi since 2011 and was the lead investor in and board member of nVision until 2018. Surbhi is a board member of Penumbra (NYSE: PEN) where she serves on both the audit and nominating committees. Additionally, she is a board member of Astia, which has both a nonprofit arm and a venture fund that serves women entrepreneurs, and is a board member of the Harker School and Draper University. Currently, Surbhi is taking a hiatus from running her own company. Instead, she derives great joy from advising and mentoring first-time startup CEOs through various organizations such as the Fogarty Institute, Y-Combinator, and the Ferolyn Fellowship. She has recently become the first Group Partner focused on healthcare and biotech at Y-Combinator.